DCLK1 and nonpapillary renal cell carcinoma: Concurrently, the EMT signature and stem cell-like properties of PLOD2-rich ccRCC xenografts were significantly repressed after DCLK1-IN-1 treatment (Fig. 8L, M), as indicated by upregulation of the epithelial marker E-cadherin, downregulation of the mesenchymal marker Vimentin, and decrease in the CSC marker Nanog, determined by RT-qPCR (Fig. 8L) and IHC (Fig. 8M) analyses.